(MET) MetLife - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59156R1086
MET: Insurance, Annuities, Employee Benefits, Asset Management
MetLife, Inc. (NYSE: MET) is one of the largest financial services companies globally, specializing in insurance, annuities, employee benefits, and asset management. Incorporated in 1999 and headquartered in New York, the company operates across six distinct segments: Retirement and Income Solutions, Group Benefits, Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. This diversified structure allows MetLife to cater to a wide range of customers, from individuals to large corporations, across various geographic regions.
MetLife’s product portfolio is extensive, covering life, dental, disability, and accident insurance, as well as annuities and pension risk transfer solutions. The company also offers administrative services for employers, prepaid legal plans, and a variety of investment products tailored for institutional clients. Its services extend to structured settlements, longevity reinsurance, and credit insurance, making it a comprehensive provider in the life and health insurance space. Additionally, MetLife provides funding agreements and synthetic guaranteed interest contracts, which are critical for organizations looking to manage their financial obligations effectively.
From a financial standpoint, MetLife is a substantial player in the industry, with a market capitalization of approximately $56.7 billion. The company’s price-to-earnings (P/E) ratio stands at 13.43, with a forward P/E of 8.46, indicating expectations of future earnings growth. Its price-to-book (P/B) ratio of 2.07 reflects the market’s valuation of its assets and liabilities. The price-to-sales (P/S) ratio of 0.80 suggests that the company is reasonably valued relative to its revenue generation. These metrics are important for investors and fund managers assessing MetLife’s position in the life and health insurance sector.
MetLife’s global presence, diverse product offerings, and significant scale make it a key player in the insurance and financial services industry. Its ability to navigate different markets and provide tailored solutions positions it as a stable investment opportunity, particularly for those seeking exposure to the life and health insurance sector. For more information, visit their website at https://www.metlife.com.
Additional Sources for MET Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MET Stock Overview
Market Cap in USD | 56,749m |
Sector | Financial Services |
Industry | Insurance - Life |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 2000-04-05 |
MET Stock Ratings
Growth 5y | 71.8% |
Fundamental | 23.3% |
Dividend | 44.3% |
Rel. Strength Industry | -6.94 |
Analysts | 4.2/5 |
Fair Price Momentum | 80.85 USD |
Fair Price DCF | 237.90 USD |
MET Dividends
Dividend Yield 12m | 2.78% |
Yield on Cost 5y | 5.24% |
Annual Growth 5y | 3.44% |
Payout Consistency | 34.6% |
MET Growth Ratios
Growth Correlation 3m | 1.1% |
Growth Correlation 12m | 85.3% |
Growth Correlation 5y | 86.1% |
CAGR 5y | 14.22% |
CAGR/Max DD 5y | 0.27 |
Sharpe Ratio 12m | 0.81 |
Alpha | 3.93 |
Beta | 0.84 |
Volatility | 20.03% |
Current Volume | 3282.8k |
Average Volume 20d | 3668.3k |
As of February 23, 2025, the stock is trading at USD 81.01 with a total of 3,282,809 shares traded.
Over the past week, the price has changed by -0.84%, over one month by -6.15%, over three months by -4.29% and over the past year by +21.02%.
Neither. Based on ValueRay Fundamental Analyses, MetLife is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.31 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MET as of February 2025 is 80.85. This means that MET is currently overvalued and has a potential downside of -0.2%.
MetLife has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy MET.
- Strong Buy: 7
- Buy: 5
- Hold: 2
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, MET MetLife will be worth about 93.8 in February 2026. The stock is currently trading at 81.01. This means that the stock has a potential upside of +15.83%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 94.7 | 16.9% |
Analysts Target Price | 94.4 | 16.5% |
ValueRay Target Price | 93.8 | 15.8% |